NR3C1 and asthma: In this phase 2a study, the first to evaluate clinical efficacy in patients with mild to moderate asthma, once daily inhaled administration of AZD7594, a novel non-steroidal selective GR modulator demonstrates improved lung function as measured by FEV1 and PEF, a reduction of airway inflammation as evidenced by a reduction in FENO and a positive impact on symptoms and asthma control.